INMODE LTD (INMD) aligns with Peter Lynch's GARP strategy, showing strong earnings growth, zero debt, and an undervalued PEG ratio for long-term investors.
InMode (INMD) is a debt-free medical aesthetics stock with strong profitability and a low P/E ratio, fitting Peter Lynch's GARP strategy for growth at a reasonable price.
Discover InMode (INMD), a top GARP stock per Peter Lynch's strategy. Strong earnings growth, zero debt, and a low PEG ratio highlight its value in the medical aesthetics sector.
InMode's Q2 2025 earnings show mixed results: revenue missed estimates at $95.6M, but EPS beat at $0.47. Shares rose 3.4% pre-market on strong profitability.
INMODE LTD (NASDAQ:INMD) offers strong growth, profitability, and an attractive valuation, making it a standout for GARP investors following Peter Lynch’s principles.
Lynch encouraged investors to look at businesses they understand and have strong financials. Does INMODE LTD (NASDAQ:INMD) align with this approach? We take a closer look.
Peter Lynch’s investment philosophy combines fundamental analysis with a deep understanding of business models. Let’s analyze if INMODE LTD (NASDAQ:INMD) meets his criteria for a solid investment.
With a strategy that emphasized steady earnings growth and a strong market position, Peter Lynch sought out long-term winners. We put INMODE LTD (NASDAQ:INMD) to the test against his stock-picking rules.
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.
